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This study aimed at estimating, in a prospective sce-
nario, the potential economic impact of a possible 
epidemic of WNV infection in Belgium, based on 2012 
values for the equine and human health sectors, in 
order to increase preparedness and help decision-
makers. Modelling of risk areas, based on the habi-
tat suitable for Culex pipiens, the main vector of the 
virus, allowed us to determine equine and human pop-
ulations at risk. Characteristics of the different clini-
cal forms of the disease based on past epidemics in 
Europe allowed morbidity among horses and humans 
to be estimated. The main costs for the equine sec-
tor were vaccination and replacement value of dead 
or euthanised horses. The choice of the vaccination 
strategy would have important consequences in terms 
of cost. Vaccination of the country’s whole popula-
tion of horses, based on a worst-case scenario, would 
cost more than EUR 30 million; for areas at risk, the 
cost would be around EUR 16–17 million. Regarding 
the impact on human health, short-term costs and 
socio-economic losses were estimated for patients 
who developed the neuroinvasive form of the disease, 
as no vaccine is available yet for humans. Hospital 
charges of around EUR 3,600 for a case of West Nile 
neuroinvasive disease and EUR 4,500 for a case of 
acute flaccid paralysis would be the major financial 
consequence of an epidemic of West Nile virus infec-
tion in humans in Belgium. 
Introduction
West Nile virus (WNV) is a vector-borne pathogen, 
member of the genus Flavivirus (family Flaviviridae); its 
main vectors are mosquitoes belonging to the Culicidae 
family, genus Culex [1,2]. The infection is maintained in 
a bird–mosquito enzootic cycle, and birds, especially 
passerines, are the primary reservoir hosts. Horses and 
humans are considered as accidental dead-end hosts, 
and are thought not to transmit the virus to other mos-
quitoes [3]. The disease generates clinical signs mainly 
in horses and humans, while most infected birds in 
Europe are not clinically affected [4]. The majority of 
horses remain asymptomatic, and about 10% of clinical 
cases develop neurological signs [5]. In humans, after 
an incubation period of 2 to 14 days, two main clinical 
pictures can be observed: an influenza-like syndrome 
(West Nile fever, WNF) and a neuroinvasive form (West 
Nile neuroinvasive disease, WNND) [4].
The virus is considered as an emerging pathogen 
in numerous parts of the world. In the United States 
(US), it has been responsible for substantial socio-
economic losses, both in the equine industry and in 
the human health sector, since its emergence in 1999 
[6]. In Europe, the virus is constantly expanding its 
geographical distribution [7] and even re-emerging in 
some areas: indeed, several equine cases have been 
reported since September 2015 in France, which also 
registered its first autochthonous human case since 
2003 [8]. To date, no autochthonous human case has 
been reported in Belgium, but the first imported case 
was described in 2013, an elderly woman who had trav-
elled to Greece [9]. As Cx. pipiens, a common mosquito 
vector of WNV in Europe [10,11], is endemic in Belgium, 
the risk of emergence in the near future should be seri-
ously considered. There is thus a need to get prepared 
in advance of such an emergence, in terms of manage-
ment strategies and their respective socio-economic 
impact. Indeed, western Europe has a recent history 
of severe economic losses associated with animal dis-
eases, e.g. with bluetongue disease epidemics in 2006 
[12] and Schmallenberg virus disease in 2011–12 [13]. 
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The objective of the study presented here was to esti-
mate, in predictive scenarios, the economic impact 
on both the equine and human health sectors of the 
spread of WNV in Belgium during an epidemic. When 
dealing with an unpredictable occurrence of a disease 
(limited knowledge about likelihoods) but with good 
knowledge of outcomes, a scenario analysis is recom-
mended [14,15]. Estimating the cost of an illness is a 
useful aid to policy decision-making. It identifies the 
different components of cost and the size of the con-
tribution of each sector, which can help determining 
mitigation measures, research and funding priorities 
by highlighting areas where inefficiencies may exist 
and savings could be made [16]. 
Methods
Determination of risk areas and populations at 
risk
In order to determine the proportion of Belgian terri-
tory representing a habitat suitable for Cx. pipiens (the 
main potential vector for WNV in Belgium), land cover 
data were extracted from the CORINE (Coordination 
de l’information sur l’environnement) land cover (CLC) 
database [17]; suitability of different land covers was 
further determined for Cx. pipiens and the proportion 
of these suitable land covers was estimated at the dis-
trict level [18]. This first step allowed us to determine 
the equine (using information from the Belgian Horse 
Confederacy) and human [19] populations at risk, at 
the district level. It was assumed that the density of 
WNV-competent birds was high and homogeneously 
Figure 1
Proportion of land compatible with Culex pipiens ecology (A), horse population (B) and human density per km2 (C), per 
district in Belgium, 2012
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distributed across the whole territory. The distribution 
of equestrian centres at district level was used to esti-
mate their potential loss of earnings as a result of an 
epidemic; data were provided by regional and provin-
cial equestrian leagues.
Equine industry
In Belgium, contrary to what is observed in many parts 
of the US, such as Texas, Colorado or Nebraska [20], 
horses are mostly used for recreational purposes, 
and their agricultural importance is very limited. A 
2010 study assessed the economic weight of equine 
industry in southern Belgium and distinguished three 
categories of horses [21]: (i) high-value horses (20%), 
mostly show horses that are cared for intensively; (ii) 
leisure horses (40%), which usually spend the winter 
indoors and the summer in pastures (horses of eques-
trian centres also fall into this category); and (iii) semi-
feral horses (40%), which spend most of their time in 
pastures, and are occasionally used for leisure (they 
are owned by individuals but are often untrained).
Economic impacts of WNV on the equine sector were 
estimated on the basis of the disease characteristics 
observed in previous European epidemics of WNV 
infection. Two scenarios based on infection rates pre-
viously estimated during outbreaks in France were 
included in the model: 8.5% infection rate [22] vs 34% 
infection rate [23]. A 10% morbidity rate was assumed, 
according to French data [5], and the number of equine 
cases was determined as follows:
a = infection rate = 8.5% vs 34% (proportion of horses 
infected by the virus, but not necessarily showing clini-
cal signs) [22,23];
0.1 = morbidity rate (10% of infected horses will develop 
symptoms of disease) [5];
b = proportion of the district (in terms of land cover) 
suitable for Cx. pipiens (used to determine the whole 
population of horses living in risk areas);
c = district total horse population.
The hospitalisation rate of neurological equine cases 
was fixed at 35% of clinically affected horses [24], and 
a 28% case fatality rate, as observed in France, was 
applied [25]. The mean length of the clinical disease 
was considered to be seven days (as was duration of 
hospital stay) [26]. The duration of an epidemic was 
estimated to be 2.5 months, with the first case reported 
on 1 August and the last case resolved on 21 October. 
This is in agreement with findings of most European 
equine cases, which are reported between August and 
October [27]. 
In terms of Belgian legislation on animal movement 
in case of epidemics of WNV infection, restrictions 
only apply for suspected and confirmed cases of WNF, 
which cannot be moved, except to be transported to a 
veterinary healthcare facility [28].
A distinction was made between non-hospitalised and 
hospitalised horses to estimate economic costs. The 
following costs were included for non-hospitalised 
horses: visits of a veterinary practitioner, serological 
diagnosis (ELISA) and reverse transcription (RT)-PCR, 
as well as treatment (non-steroidal anti-inflammatory 
medicine). Hospitalised horses were considered to be 
seen first by a veterinary practitioner before being 
referred to a veterinary hospital. The estimation of costs 
included also: costs of a seven-day stay, complemen-
tary examinations (blood analysis, radiography, punc-
ture of cerebrospinal fluid, diagnosis and neurology) 
and seven-day treatment (steroidal and non-steroidal 
anti-inflammatory medicine, intravenous fluids) [24]. 
For horses that died or had to be euthanised, trans-
port and destruction of cadavers, as well as replace-
ment value, were considered for the three categories of 
horses (i.e. high-value, leisure and semi-feral).
The cost of vaccination was also included in the esti-
mations. According to current Belgian legislation, the 
vaccination of equids against WNV is not mandatory; 
nevertheless, the Minister of Agriculture could modify 
that decision in case of epidemics [29]. Two vaccina-
tion scenarios were thus applied in our model in order 
to investigate the potential impact of such a preventive 
measure on the estimation of costs: the first scenario 
relies on the vaccination of the entire equine popula-
tion (except sick horses), while the second scenario 
considered the vaccination of horses in risk areas only. 
Primary vaccination consists of two doses, the sec-
ond dose being administered 3–5 or 4–6 weeks later, 
depending on the vaccine used; indeed, in Belgium, 
two vaccines are registered for horses older than 5–6 
months [30].
According to the Belgian Federal Authorities, an out-
break is confirmed when there is proof that the WNV 
is effectively transmitted by a local infected vec-
tor population, competent for transmitting the virus 
[28,29]. Consecutively, passive clinical surveillance 
is enhanced and active serological surveillance is 
implemented for horses in the area where the epide-
miological investigation is carried out (within a 50 km 
radius) [28,29]. Active surveillance in horses consists 
of an ELISA (detection of IgG and IgM) performed on 
blood samples, by the National Reference Laboratory 
in Brussels. In order to determine the number of blood 
samples that would need to be taken, estimation was 
made through Win Episcope 2.0 software, consider-
ing a sample size needed to detect the disease, with a 
5% expected prevalence and 95% confidence interval. 
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Figure 2
Estimated number of patients with West Nile neuroinvasive disease, by employment category and infection rate scenario, 
following an epidemic of West Nile virus infection in Belgium, 2012
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These estimates were based on statistics related to the labour market, e.g. employment rate (according to sex or status) of working patients. Costs and losses were not 
estimated for children under 15 years of age and students.
Shaded boxes show the number of patients estimated for each professional category considered in our estimations of costs (related to productivity losses).
a Active individuals include all persons of working age, who carry out a paid activity (population active occupied) and job seekers (population active unoccupied/
unemployed) [61].
b Inactive individuals include all persons, even those under 15 years of age, who are not economically active [61].
c Occupied individuals include all persons, aged 15 years and above, who have a paid job (self-employed, employees and workers).
d We considered unemployed people not only to be those who did not work (and were entitled to unemployment benefit), but also people not on the labour market, such as 
housewives/house husbands.
e In the ‘non-salaried’ category, only self-employed people were considered for the estimate of losses. Indeed, no losses can be estimated for unpaid helpers; losses for 
employers were those estimated for occupied people in our study.
f We made a distinction between employees (who generally carry out intellectual work) and workers (who mainly carry out manual tasks).
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For equestrian centres, serology was also performed 
on asymptomatic horses located in the same cen-
tre, as suggested in the WNV scenario elaborated by 
the Belgian Federal Agency for the Safety of the Food 
Chain [28]. Active surveillance was considered to be 
implemented throughout the epidemic (13 weeks), with 
a 15-day frequency [31], which means six sampling 
periods.
In Belgium, any movement of a live animal suspected 
to have viral encephalitis is prohibited [29]. As it is 
also mandatory to isolate horses that are suspected or 
confirmed to have WNV infection [29], associated addi-
tional costs of feed (cereals, hay and water) and litter 
(straw) were estimated for the duration of the epidemic 
for all equine cases (hospitalised and non-hospitalised 
horses), because suspected cases are assumed not to 
be left out on pastures.
The loss of income for affected equestrian centres 
(mean of 20 horses for public use per centre [21]), of 
the 830 registered in the country, was also estimated, 
considering the mean number of days of lost-use for 
equids clinically sick and recovering [32]. All assump-
tions made in our study are compiled in Table 1.
Public health
In humans, two main clinical disease forms are 
described: WNF and WNND [33]. Our study only included 
patients affected by WNND for the estimation of costs.
 
The potential consequence of WNF would logically be 
for the affected person to visit to a general practitioner 
(GP) and miss five days at work [34]. It seems unlikely, 
however, that all affected people would consult their 
GP. The impact on productivity should be limited, as 
these people would not be replaced for such a short 
length of absence, and they would have to deal with 
the backlog on returning to work. Alternatively, many 
people with WNF could miss work for less than five 
days (e.g. self-employed people who lose a net salary 
when missing a working day). 
Three main syndromes may be observed in case of 
neuroinvasive disease: meningitis, encephalitis and 
acute flaccid paralysis (AFP) [4]. As a previous study 
estimated the costs for meningitis and encephalitis to 
be quite similar [35], our work distinguished between 
two main syndromes: meningoencephalitis and AFP.
The human population at risk was determined per dis-
trict according to the same procedure as for equids. 
Two scenarios were tested, based on infection rates 
estimated during an equine WNV outbreak in southern 
France in 2000 [36].
The number of WNND cases was calculated as follows:
a = district total population;
b = proportion of the district (in terms of land cover) 
suitable for Cx. pipiens;
c = infection rate (2%, as estimated among 1,104 blood 
donors living outside the region of the 2000 equine 
epidemic of WNV infection in southern France, or 15%, 
determined among 1,053 blood donors living in the epi-
demic zone [36]);
0.007 = percentage of patients develop WNND [37].
A 0.7% morbidity rate for WNND was considered, which 
means that among infected patients, 0.7% will develop 
the neuroinvasive form requiring hospitalisation [37]. 
Infection rates were assumed to be uniformly distrib-
uted in the population, without considering criteria 
such as age and sex, as they have not been identi-
fied as risk factors in an important case–control study 
performed in Greece in 2010 [38]. Of 197 WNND cases 
reported in Greece in 2010, 3% were classified as AFP 
cases [39]. An 11% case fatality rate was applied, as 
reported for the whole of the European Union (EU) in 
2012 [7]. All WNND cases were assumed to be hospital-
ised, as considered in a previous work [40]. The mean 
hospitalisation length of stay was nine days (Philippe 
Leonard, personal communication, September 2011). 
No vaccine is currently available for humans and the 
only treatment is supportive care [4]. All assumptions 
made in our study are shown in Table 1.
As for the equine sector, economic impacts were esti-
mated taking into account several aspects, such as 
medical and hospital costs, costs for home care, com-
pensation paid for the death of a patient and costs 
associated with work absenteeism. Short-term initial 
costs included a visit to a GP. In Belgium, the health-
care system is divided into state and private sectors. It 
is funded by a combination of social security contribu-
tions and health insurance funds. Healthcare insurance 
is mandatory: patients generally pay the costs and are 
then reimbursed for part of the charges. Individuals 
can also improve their cover by taking out private 
insurance, which allows them to be fully refunded for 
all medical costs [41]. Inpatient costs for acute care 
and rehabilitation were also considered: hospital stay 
(room and board charges), complementary tests and 
examinations (e.g. electroencephalogram, cerebrospi-
nal fluid analysis, visit of a neurologist, heart monitor-
ing, imaging, laboratory investigation and serology) 
and pharmacy/medical supplies (treatment charges: 
pharmacy, drugs such as antibiotics and antiviral med-
icine, and anti-epileptics, injections, medical supplies, 
intravenous fluids and intravenous therapy). 
Costs related to hospital charges were indexed, as 
information was collected from hospital records 
concerning a patient hospitalised in Belgium for 
WNND in 2004 (encephalitis with epilepsy) (Philippe 
Leonard, personal communication, September 2011). 
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Table 1a
Model parameters for estimating economic impact of an epidemic of West Nile virus infection in Belgium, based on 2012 
values
Parameter Value Unit Source
Vectors 
Proportion of territory (land cover) representing a 
habitat suitable for Culex pipiens Variable % [18]
Duration of the epidemic 2.5 Months [7]
Horses 
District horse population Variable Number Belgian Horse Confederacy, Jean-Pierre Devos, personal communication, July 2013
Equestrian centres (per district) Variable Number Belgian Regional and Provincial Equestrian leagues, Jan Deboitselier, personal communication, July 2013
Horse infection rate (proportion of the horse 
population living in the risk areas infected by the virus) 8.5 vs 34 % [22,23]
Horse morbidity rate (will develop clinical signs of 
disease) 10 % [5]
Hospitalisation rate for neurological cases 35 % [24]
Horse case fatality rate (mortality among neurological 
cases; the most severe cases being hospitalised) 28 % [25]
Mean length of the clinical disease (duration of 
hospital stay for hospitalised horses) 7 Days [26]
Active surveillance (screening) ELISA results NA [28,29]
Duration of active surveillance (whole epidemics) 13 Weeks [28]
Frequency of sampling – active surveillance 15 Days [31]
Detection of the disease – 5% expected prevalence 
(95% confidence interval)a Variable Number Win Episcope 2.0; [24]
Mean number of horses per equestrian centre (for 
public use; not privately owned) 20 Number [21]
Public health 
District human population Variable Number [19]
Human infection rate (proportion of the population 
living in the risk areas infected by the virus) 2 vs 15 % [36]
Human morbidity rate for WNND (all patients assumed 
to be hospitalised) 0.7 % [37]
Proportion of AFP among WNND cases (all assumed to 
be > 65 years-old) 3 % [39]
Human case fatality rate (mortality among patients 
with WNND) 11 % [7]
Mean age of deceased patients 78 Years [58]
Mean hospitalisation length of stay 9 Days Philippe Leonard, personal communication, July 2011
Home recovery
Duration (working days) 20 Days Philippe Leonard, personal communication, July 2011
Daily cost for a home nurse (two visits a day – one hour 
a day) 16 Euros [59]
Daily cost for a caregiver (eight hours a day) 62 Euros [60]
AFP: acute flaccid paralysis; NA: not applicable; WNND: West Nile neuroinvasive disease.
a The decision to select 5% expected prevalence arose from the results of Durand et al. in France [22] who estimated an 8.5% prevalence in a 
West Nile virus outbreak in horses in 2000; thus, a 5% threshold seemed realistic.
b Active individuals include all persons of working age, who carry out a paid activity (population active occupied) and job seekers (population 
active unoccupied/unemployed) [61].
c We considered unemployed people not only to be those who did not work (and were entitled to unemployment benefit), but also people not 
on the labour market ,such as housewives/house husbands.
d We made a distinction between employees (who generally carry out intellectual work) and workers (who mainly carry out manual tasks).
e All information regarding costs for a hospitalised case was obtained from hospital records regarding a patient hospitalised in Belgium for 
WNND in 2004: we therefore adapted the costs to 2012 values, taking into account the evolution of the consumer price index.
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We estimated the costs in 2012: thus a mean annual 
growth rate of 1.7% was applied to adapt healthcare 
prices to the evolution of the consumer price index 
for the eight-year period and convert them into 2012 
values [42]. Hospitalisation costs were estimated to 
be 1.25 times higher for AFP cases than the costs for 
patients affected by WNND, based on estimates used 
in a study in the US [35].
Costs associated with the death of patients were esti-
mated through an ex post approach, as part of human 
capital theory [43], and consisted of insurance claims 
paid to beneficiaries. In order to obtain representa-
tive data, a directory of accidents from a car insurance 
branch of a Belgian insurance company was analysed 
over a five-year period (2009–13). The insurance claim 
considered only covered the economic loss, and not 
the suffering of close relatives (i.e. pretium doloris). 
Considering a 9.78% annuity conversion rate, esti-
mated according to the life expectancy of a 78 year-old 
person, the insurance claim reached EUR 9,800, on the 
basis of a 1.5% annual discount rate.
Additionally, a mean occupational interruption of 30 
working days (for symptomatic disease and recov-
ery) was taken into account to estimate productiv-
ity lost [40]. To establish the distribution of patients 
in different employment categories, statistics rela-
tive to the labour market – such as employment rate 
according to age and sex, status of working patients 
(self-employed vs employed) and mean gross monthly 
wages – were provided by the Belgian Federal Public 
Service of Economy, Small and Medium Enterprises, 
Self-employed and Energy, for 2012. We made a dis-
tinction between employees (who generally carry out 
intellectual work) and workers (who mainly carry out 
manual tasks). 
Parameter Value Unit Source
Productivity lost
Percentage of men in the population 49.06 % [19]
Percentage of women in the population 50.94 % [19]
Activity rateb in people aged 15–64 years – men 72.5 % [19]
Activity rateb in people aged 15–64 years – women 61.3 % [19]
Employment ratec – men 66.9 % [19]
Employment ratec – women 56.8 % [19]
Proportion of employeesd 62.0 % [19]
Proportion of workersd 38.0 % [19]
Mean annual growth (to adapt 2004 healthcare pricese 
to 2012 values) 1.7 % [42]
Costs associated with the death of a patient (insurance 
claims paid to beneficiaries) 9,800 Euros
Belgian insurance company, personal communication, 
November 2014
Mean occupational interruption to estimate 
productivity lost (working days) 30 Days [40]
Mean gross monthly salary – Men (2012) – Employee 3,668 Euros [19]
Mean gross monthly salary – Men (2012) – Worker 2,749 Euros [19]
Mean gross monthly income – Men (2012) 
– Self-employed 3,700 Euros [19]
Mean gross monthly salary – Women (2012) 
– Employee 3,372 Euros [19]
Mean gross monthly salary – Women (2012) – Worker 2,527 Euros [19]
Mean gross monthly income – Women (2012) 
– Self-employed 3,413 Euros [19]
AFP: acute flaccid paralysis; NA: not applicable; WNND: West Nile neuroinvasive disease.
a The decision to select 5% expected prevalence arose from the results of Durand et al. in France [22] who estimated an 8.5% prevalence in a 
West Nile virus outbreak in horses in 2000; thus, a 5% threshold seemed realistic. 
b Active individuals include all persons of working age, who carry out a paid activity (population active occupied) and job seekers (population 
active unoccupied/unemployed) [61].
c We considered unemployed people not only to be those who did not work (and were entitled to unemployment benefit), but also people not 
on the labour market ,such as housewives/house husbands. 
d We made a distinction between employees (who generally carry out intellectual work) and workers (who mainly carry out manual tasks). 
e All information regarding costs for a hospitalised case was obtained from hospital records regarding a patient hospitalised in Belgium for 
WNND in 2004: we therefore adapted the costs to 2012 values, taking into account the evolution of the consumer price index.
Table 1b
Model parameters for estimating economic impact of an epidemic of West Nile virus infection in Belgium, based on 2012 
values
8 www.eurosurveillance.org
Results
Habitat suitability in Belgium for Cx. pipiens is illus-
trated at the district level in Figure 1 (panel A). The pro-
portion of suitable habitat was the basis for estimating 
the number of individuals at risk (in terms of propor-
tions of the whole population of the district). Horse 
and human populations are shown in panels B and C, 
respectively.
Equine industry
Estimates of economic costs associated with WNF per 
horse are summarised in Table 2.
When considering national estimations (Table 3), the 
main costs would be related to the replacement of 
dead or euthanised horses, followed by hospitalisation 
charges. If vaccination was implemented (whole terri-
tory or areas at risk), associated costs would then rep-
resent the major expense.
At national level, the lost revenue for equestrian cen-
tres following an outbreak would reach between EUR 
113,022 and EUR 450,450 for the 8.5% and 34% infec-
tion rate scenarios, respectively, assuming that two 
clinically sick horses per equestrian centre were not 
used during the time of clinical disease/treatment and 
recovery. The occurrence of WNV infection in these 
equestrian centres also implied the sampling of all 
horses located in the same centre (mean of 20 horses 
per centre). Detailed estimations can be consulted in 
supplementary material [44-47].
Public health aspects
The estimated distribution of WNND cases, for both 
infection rate scenarios, according to the criteria used 
is shown in Figure 2. No productivity loss was esti-
mated for people aged over 65 years and for patients 
with AFP, as they are all assumed to be retired. Nor 
did we estimate productivity lost for caregivers (often 
another family member), who might miss work to care 
for the recovering patient after hospital discharge. 
Home care costs were nevertheless estimated for sur-
viving hospitalised patients during their recovery (20-
day period).
The costs incurred per patient with WNND, as well as 
the associated productivity losses, are summarised in 
Table 4.
National estimates, as shown in Table 5, highlight 
the importance of hospital costs (around 50% of total 
costs), compared with those for home care during 
recovery (about 30% of total costs). Detailed estima-
tions can be consulted in supplementary material 
[44-47].
Discussion
We estimated, in a prospective scenario, the economic 
impact of a possible epidemic of WNV infection in 
Belgium, according to different infection rate scenarios 
in horses and humans. Considering the whole territory 
would be concerned might be an overestimation (worst-
case scenario). In view of epidemics reported in the EU 
to date, spatial extension might be less pronounced. 
All conditions for epidemic spread are met in the north-
ern part of the country, as Cx. pipiens habitat and areas 
of human density are closely related, as are areas with 
horse populations. Our selected infection rates might 
seem low compared with those in WNV-endemic areas 
of Africa, where seroprevalence of more than 90% was 
detected in horses in some places [48], but they reflect 
better the dynamics of the virus in Europe. Applying 
infection rates reported in epidemic situations allowed 
us to identify substantial costs and losses associated 
with the disease, both in horses and humans.
Impact on the equine industry
The total estimated cost for treating a horse affected 
by neurological disease due to WNV in 2012 would 
be more than estimated in the US, in Colorado and 
Nebraska, in 2002 [32]. Intensive care for moderate 
cases (wobbly gait, difficulty eating, signs of colic, 
reluctance to move, hypersensitivity to noise and 
touch, and altered awareness) was estimated to cost 
USD 400 (EUR 381) (equivalent to USD 539 (EUR 408) 
in 2012). For hospitalised horses showing severe neu-
rological disease, we estimated such costs to reach 
EUR 741 (USD 917). Our estimates are more in line with 
a later survey performed in Texas, US, for 2002, in 
which veterinarians estimated the cost of treatment of 
a severe WNND equine case to be over USD 701 (EUR 
668) (when considering a mean annual growth rate of 
1.7%, as mentioned above) [49].
Vaccination is the main cost associated with epidemic 
spread of WNV in horses: the strategy, if implemented, 
would have a major economic impact, as vaccinating 
the whole equine population (100% coverage scenario) 
would cost over EUR 30 million. The time needed to pro-
duce and commercialise enough vaccine doses would 
not be less than six to nine months. Thus we assume 
that complete vaccination of the whole population of 
horses could be achieved by the following vector sea-
son. The vaccine should be administered to horses 
aged five to six months and above [30]: unfortunately, 
the proportion of animals falling into this age category 
was not available, which would have allowed us esti-
mate more precisely the costs. Thus the vaccination 
costs detailed here are probably overestimates (based 
on a worst-case scenario).
A recommendation to keep horses indoors would 
not be very effective against Cx. pipiens if additional 
measures such as mosquito nets or fans are not 
installed, as these mosquitoes are also active indoors. 
Nevertheless, from a practical point of view, it is prob-
able all horse owners would not have the possibility or 
willingness to follow such a recommendation and to 
invest in adequate protective equipment. Furthermore, 
once horses are completely vaccinated, such a recom-
mendation would no longer be relevant. The lost rev-
enue for equestrian centres, due to affected horses not 
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being used during the time of clinical disease/treat-
ment and recovery, is very similar to the losses Gavlan 
et al. estimated in Texas, US, for 2002 [49]. 
As a prospective study, our estimations have, of 
course, some limitations. Several aspects were not 
taken into account to estimate economic impact, such 
as: (i) the costs of surveillance in birds (wild avifauna 
and sentinel domestic poultry), as it has already been 
implemented since 2010, and would not generate addi-
tional costs [50]; (ii) entomological surveillance, as 
this has not been clearly defined in the Belgian context 
to date; (iii) the preventive action of applying repel-
lents, as this is suspected to be difficult to implement 
in the field [51] as people’s perceptions and behav-
iour towards protecting themselves and their horses 
Table 2
Economic losses and costs associated with West Nile virus fever in the equine industry following an epidemic of West Nile 
virus infection in Belgium, estimated per horse, 2012 values
Economic impact Value in euros 
Disease in horse 
Visit of veterinary practitioner 42
Hospitalisation (7 days’ duration)a
Stay of the horse 69
Veterinarian specialists (internal medicine, neurology) 85
Complementary examinations (blood sampling and analysis, X-rays, CSF puncture and analysis) 191
Medical treatment (NSAID, SAID, supportive treatment) 396
No hospitalisation
Medical treatment (NSAID) 27
Diagnosis (serology, RT-PCR) 76
Indirect costs – containment of cases in stables 
Extra feed 
Hospitalised surviving horseb
High-value horse 33
Leisure horse 19
Semi-feral horse 12
Non hospitalised horsec
High-value horse 39
Leisure horse 22
Semi-feral horse 14
Extra bedding 
Hospitalised surviving horseb
High-value horse 44
Leisure and semi-feral horse 22
Non-hospitalised horsec
High-value horse 53
Leisure and semi-feral horse 26
Management of horse mortality
Transport, destruction of cadaver 70
Replacement value for dead/euthanised horse
High-value horse 10,000
Leisure horse 4,000
Semi-feral horse 2,000
Loss of earnings
Per affected horse for rentd 1,638
Vaccination
Two doses of vaccine, veterinary costs 144
CSF: cerebrospinal fluid; NSAID: non-steroidal anti-inflammatory drug; RT: reverse transcription; SAID: steroidal anti-inflammatory drug. 
a Hospitalised horses were assumed to be the most severely affected, when considering nervous clinical signs.
b Mean income per horse (39 workdays during clinical disease and recovery; three hours of work a day and one day off per week).
c A 42-day recovery period was considered for a horse that was not hospitalised. 
d Regarding indirect costs and containment of cases indoors, a duration of 35 days was considered for recovery of a horse after its discharge 
from a veterinary hospital.
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is unknown; and (iv) impact of epidemic spread of 
WNV on trade of horse semen, even though the World 
Organisation for Animal Health (OIE) recommends that 
its member states should not impose trade restrictions 
on dead-end hosts such as horses [52]. In addition, 
some horse owners might have their horses insured, 
particularly if they are high-value horses: that parame-
ter was not considered in our study due to lack of data.
Impact on public health
Regarding the economic consequences for the human 
health sector, our estimations of hospital costs (EUR 
3,553 for a WNND case and EUR 4,441 for an AFP case) 
are less than USD 8,274 (EUR 7,890), which was the 
median cost of inpatient treatment calculated for a 
WNV disease epidemic in Louisiana, US, in 2002 [53], 
and far below the USD 33,143 (EUR 28,094) estimated 
by Barber et al. in California, US, in 2005 [40]. In our 
study, several criteria were not taken into account, 
such as residual neurological after-effects. 
Even if a diagnostic test would be performed systemati-
cally for WNND patients, results of analyses arrive late, 
sometimes after hospital discharge (Philippe Leonard, 
personal communication, July 2011). Furthermore, 
confirmation of diagnosis would not provide an alter-
native to effective palliative medical care.
It is not surprising that hospital costs were higher than 
productivity losses, as more elderly patients develop 
neuroinvasive disease [4]; no productivity loss was 
estimated for people aged 65 years and above, as they 
are not considered as part of the labour market any 
more. Home care of recovering patients was the sec-
ond most expensive cost. It is important to note that, 
in Belgium, professional home care services are partly 
refundable through the healthcare system, so family 
members are not systematically obliged to miss work 
to provide care to the patient. They can turn to these 
professionals to take care of them. Nevertheless, it was 
decided to include home care costs in our estimations. 
Our WNND scenario was based on estimates related to 
the overall population of areas at risk, infection rate 
and morbidity rate for WNND. Some cases could pass 
unnoticed at the beginning of the epidemic. An mean 
nine-day hospitalisation stay was selected, which is 
slightly longer than the length reported in a five-year 
survey of initial and long-term medical and lost-pro-
ductivity costs for patients hospitalised in Colorado, 
US, in 2003 [35]. Higher costs are expected for AFP 
Table 3
Economic losses and costs associated with West Nile virus fever in the equine industry following an epidemic of West Nile 
virus infection in Belgium, by infection rate scenario, estimated at national level, 2012 values
Economic impact
8.5%  
infection rate scenario
34.0%  
infection rate scenario
Cost in euros Number Cost in euros Number
General
Hospitalisation (7 days) 278,748 356 1,116,558 1,426
No hospitalisation 145,640 662 582,560 2,648
Diagnosis (serology, RT-PCR) 77,368 1,018 309,624 4,074
Management of cadavers 7,000 100 27,930 399
Active surveillancea (serology) 147,888 24,648b 147,888 24,648b
Containment of cases indoors – maintenance costs 47,118 918 188,564 3,674
Replacement value
Total 440,000 100 1,750,000 399
High-value horses 200,000 40 790,000 79
Leisure horses 160,000 40 640,000 160
Semi-feral horses 80,000 20 320,000 160
Total (general and replacement value) 1,143,762 NA 4,123,124 NA
Loss of earnings for equestrian centres
Amount 113,022 69 450,450 275
Vaccination costs (2 doses of vaccine, veterinary costs)
100% coverage 33,091,632 229,803 32,651,712 226,748
Areas at risk 17,105,040 118,785 16,665,264 115,731
NA: not applicable; RT: reverse transcription.
The population of horses was subdivided into three categories: 20% high-value horses, 40% leisure horses and 40% semi-feral horses [21]. 
a Expected 5% prevalence (set at this level to be realistic compared with that in [22]) determined according to the equine population per 
district (risk areas)). Six sampling periods would be implemented, with sampling planned every two weeks [31]. If a horse is affected in a 
rental centre, all other animals should be regularly tested as well (mean of 20 horses per rental centre) [21].
b Number of tests performed. 
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cases, due to longer hospitalisation and a higher lost 
productivity [35].
As for the equine part of the study, our estimates for 
the public health section have several limitations, as 
the study was performed prospectively. The control 
of vectors should be recommended to individuals and 
to public health authorities in case of a severe epi-
demic, but associated costs were not included in the 
estimations, in contrast to a previous study [35]. We 
did not consider impact of preventive use of chemical 
repellents or anti-mosquito infrastructural measures 
applied in houses (such as mosquito nets), as it is 
unpredictable which option people would choose, if 
any. We consider that emergency aerial spraying, even 
if proven to be effective in reducing mosquito popula-
tions and the number of human cases of WNV infection 
in the US [40], would not be the first option of vector 
control in Belgium, given the substantial environmen-
tal risks; furthermore, in our opinion, such a measure 
would not be easily accepted by the population. Also, 
the risk of mosquitoes developing resistance against 
insecticides should not be neglected. Furthermore, 
a recent study identified knowledge gaps concerning 
vector control in Europe and urged that the most appro-
priate and environmental friendly control strategies 
should be identified, given the reduced availability of 
products for mosquito control in recent years [54].
Neither outpatient costs (e.g. nursing home, transpor-
tation and child care) nor long-term costs (e.g. durable 
medical equipment, medication, medical appointments 
and institutional care) were taken into account, unlike 
previous estimations [35]. Actual costs might thus be 
higher. Inclusion of such costs would have been diffi-
cult, however, as it was a predictive study. Long-term 
costs of potential WNND after-effects, such as cost of 
treatment in rehabilitation facilities, were not evalu-
ated, unlike a previous study in the US [53], as our 
scenario assumed the absence of after-effects in recov-
ering patients (which is far from being the case when 
considering AFP).
The financial burden for the Belgian public health 
agency was assumed to be already included in its 
annual financing package. Communication about the 
epidemic by public agencies (e.g. production of bro-
chures for the whole population or information aimed 
at horse owners) could be a cost to consider as well, 
but is difficult to estimate when taking a predictive 
approach, as it would probably be related to the impor-
tance of the epidemic.
The screening of blood and organ donors (most human 
infections being asymptomatic [4]) could be recom-
mended, especially for those who return from an area 
with ongoing transmission of WNV in humans. Blood 
donations from WNV-positive donors should thus be 
deferred, as transmission of WNV through blood trans-
fusion and organ donation has been well assessed 
[55]. The European Commission established a deferral 
period for prospective donors of 28 days after leaving 
an area with ongoing transmission of WNV in humans 
[56]. Blood and organ screening should be considered 
as an important contribution to epidemiosurveillance 
and epidemiovigilance systems [57] (useful to detect 
emergence of the disease). 
The US healthcare system is quite different from that 
in western Europe. In Belgium, in the event of absence 
for medical reasons, a worker (at least an employee) 
does not lose their salary: the loss is thus borne by 
the employer. Nevertheless, for long periods of illness, 
Table 4
Economic losses and costs of West Nile neuroinvasive 
disease in humans following an epidemic of West Nile 
virus infection in Belgium, estimated per human case, 
2012 values
Economic impact Cost in euros
Initial visit, to a general practitioner 23
Diagnostic tests (serology) 21
Hospitalisation: WNND case
Total hospitalisation cost 3,553
Staya (9 days hospitalisation) 739
Pharmaceutical expenses 926 
Provision of servicesb 1,888
AFP casec
Total hospitalisation cost 4,441
Home cared (during a 30-day home recovery period)
Costs 2,340
Productivity lost due to work absenteeism
Men 
Employeee 5,502
Workere 4,124
Self-employed 5,550
Women
Employeee 5,058
Workere 3,791
Self-employed 5,120
Compensation
Paid to beneficiaries after the death of a patientf 9,800
AFP: acute flaccid paralysis; WNND: West Nile neuroinvasive dis-
ease.
a Includes costs of hospital stay, medical services, patient’s share 
of the costs, initial clinical tests and daily pharmacy costs.
b Includes monitoring of vital functions, medical imaging, clinical 
biology, neurology, etc.
c AFP occurs in 3% of all WNND cases [39]. Hospitalisation costs are 
1.25 higher for AFP cases compared with those for WNND cases 
[35].
d Including costs for a nurse and caregiver. Home care costs are 
underestimated for AFP cases, as recovery can take several 
months [62].
e We made a distinction between employees (who generally carry 
out intellectual work) and workers (who mainly carry out manual 
tasks).
f Estimated from compensation paid to beneficiaries by a Belgian 
insurance company following the death of a 78 year-old person 
in a car accident (median age of patients who died from WNND 
being 78 years).
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it is possible for an employer to hire interim staff, to 
replace the worker on sick leave. Thus productiv-
ity losses could be attenuated, even if a replacement 
contract generates additional costs for the employer 
(especially if they rely on employment agencies).
Conclusion
The originality of our study is its prospective approach 
(preparedness) compared with previous works estimat-
ing economic impact of WNV in the US (retrospective 
studies). Our two scenarios relied on the variation of 
one parameter only, i.e. infection rate, while almost all 
parameters entered in the model are subject to uncer-
tainty; a multifactor sensitivity analysis would have 
certainly widened the range of estimates. Better qual-
ity information is needed to predict the cost of a WNV 
outbreak in Belgium with more accuracy. In horses, if 
animal health authorities were to decide to recommend 
or to make vaccination compulsory, the choice of the 
strategy would have major consequences in terms of 
costs. Furthermore, animal health authorities would 
have to consider the delay involved in producing a high 
number of vaccine doses. It would thus not be possible 
to vaccinate the entire horse population during a first 
hypothetical epidemic. Targeted vaccination of horses 
at risk (living in habitat suitable for Cx. pipiens) could 
be a first-line preventive measure. A cost–benefit anal-
ysis of horse vaccination versus vector control is worth 
investigation. In humans, hospital charges would be 
the major financial consequences of an epidemic of 
WNV infection. It is thus essential to invest in research 
on preventive measures in the European context, e.g. 
through the development of a human vaccine (as none 
is commercialised to date) and integrated biological 
control of vectors, on a large scale. Integration of these 
impacts in healthcare plan/insurance schemes are of 
prime importance in terms of preparedness.
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